VMocion Raises $3M in Seed Funding to Propel Advancements in Virtual Motion Technologies

The seed funding secured will play a pivotal role in advancing VMocion's technologies, enhancing user experiences across a diverse range of immersive and motion-oriented applications.

by

Entertainment technology company VMocion, based in Scottsdale, Arizona, has announced the successful closure of a $3 million seed round aimed at advancing its innovative VMocion 3V™ and WAIV™ technologies. Notable investors in this round include AZ Crown and Mayo Clinic, with Eric Crown of Insight Enterprises Inc1. joining the Board of Directors alongside VMocion principals and representatives from Mayo Clinic.

VMocion’s 3V™ technologies introduce a novel concept where users can not only see but also feel the motion portrayed on screen, creating a comprehensive, all-sensory experience. This innovative approach redefines how individuals experience motion in virtual reality (VR), augmented reality (AR), and extended reality (XR) applications. Importantly, it addresses a physiological aspect that has not been effectively commercialized, while also preventing VR sickness—a common challenge in immersive experiences. By providing a virtually stimulated sense of physical motion that corresponds to on-screen motion, VMocion enables more users to engage in such experiences for longer periods without discomfort or fatigue.

Motion sickness, often induced when the sensed motion doesn’t align with the visual motion, is a significant challenge affecting approximately 30% of people under various travel conditions and experiences. VMocion’s WAIV™ technology aims to address this issue by raising the threshold of the vestibular sensation of motion, mitigating the brain’s perception of motion and eliminating visual-vestibular mismatch. This breakthrough has the potential to prevent motion sickness for the majority of individuals who are susceptible, presenting a substantial impact on related markets, including travel, amusement parks, and flight simulation.

VMocion holds an exclusive license to select Mayo Clinic patented technologies that have undergone validation through human studies, demonstrating safety and effectiveness. These technologies offer a non-pharmaceutical and non-invasive means to overcome VR illness and motion sickness.

The applications of VMocion’s technologies extend beyond entertainment to various consumer and commercial sectors, including gaming, transportation (planes, trains, automobiles, marine travel), amusement parks, electric and autonomous vehicles, flight simulation, pilot training, and military applications.

The seed funding secured will play a pivotal role in advancing VMocion’s technologies, enhancing user experiences across a diverse range of immersive and motion-oriented applications.

Related Stories

Latest News Stories

Discover more from Silicon Valley Journals

Subscribe now to keep reading and get access to the full archive.

Continue reading